|
Product tested | Study design | No. of patients | Main finding | Reference |
|
Iscador M, Iscador Q, and Iscador P | Prospective nonrandomized and randomized matched-pair trial | 91 pairs | Patients’ self-regulation was enhanced | [91] |
Abnoba-Viscum (r) | Retrolective cohort study | 689 | HRQoL was improved | [92] |
Lectin-standardized mistletoe extract (sME) | Cohort study | 1248 | HRQoL was improved, relapse free interval was prolonged | [93] |
Viscum album L., Iscador | Comparative, randomized cohort study | 1442 | Side effects caused by chemotherapy were reduced. Survival was improved | [68] |
Helixor A | Randomized multicentric trial | 68 | Side effects of chemotherapy were alleviated | [69] |
Standardized mistletoe extract PS76A2 (Lektinol) | Randomized and double blind trial | 272 | HRQoL was positively affected | [94] |
Standardized mistletoe extract PS76A2 (Lektinol) | Randomized, double blind trial | 352 | Survival time was prolonged during and after chemotherapy | [70] |
Helixor A | Double blind controlled trial | 23 | No difference in HRQoL was observed in both placebo and Helixor A treated groups | [95] |
Iscador | Controlled Randomized and nonrandomized | 122 pairs | Survival time was significantly enhanced | [96] |
Helixor | Comparative epidemiological cohort study | 741 | HRQoL was improved; side effects of chemotherapy were reduced | [71] |
Iscador M spezial | Randomized controlled trials | 65 | No effect on HRQOL was observed; adverse reaction to chemotherapy was reduced | [72] |
Iscador M spezial | Prospective open 2-armed nonrandomized trial | 33 | Lower incidence of nausea was observed; HRQoL was improved | [97] |
Iscador M spezial | Randomized open label trial | 95 | Better HRQoL was developed, trend toward neutropenia reduction was observed | [73] |
Iscador M | Case study | 1 | Dose-dependent benefits were obtained in decreasing fatigue | [98] |
Abnoba-Viscum Mali | A noninterventional and prospective trial | 270 | Adverse reactions to chemotherapy were reduced. HRQoL was improved | [74] |
Iscador M spezial | Randomized clinical trial | 95 | HRQoL was improved | [99] |
Iscador P, Qut, and M | Multicenter, controlled, and retrolective | 3376 | Tumor related symptoms decreased significantly and overall survival was prolonged | [100] |
Isorel, Iscador Qu, M or P, abnoba-Viscum Qu or A | Multi cancer cohort study | 4 | HRQoL was improved | [101] |
Iscador M spezial | Noninterventional follow up trial | 57 | HRQoL was enhanced; neutropenia was prevented | [75] |
Helixor A | prospective randomized open-label | 95 | HRQoL improved significantly | [102] |
|